Skip to main content
SpringerLink
Log in

Preferred Drug Lists and Medicaid Prescriptions

  • Original Research
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Background: When Medicaid preferred drug lists (PDLs) are implemented, they may impose indirect costs on prescribing physicians and Medicaid patients, leading to an unintended reduction in the number of Medicaid prescriptions filled.

Objective: To test retrospectively the proposition that PDLs adversely affect the number of Medicaid prescriptions filled.

Data and methods: We compared three ‘test’ states (Alabama, Texas, and Virginia) that implemented PDLs with restrictions on the prescription of statins with three ‘control’ states (New Jersey, North Carolina, and Pennsylvania) that did not implement drug access restrictions. We conducted the analysis at the county level and used a differences-in-differences approach that allows for county and time-period fixed effects.

Results: We found that PDLs adversely impacted several measures of filled Medicaid prescriptions in the ‘test’ states relative to the ‘control’ states.

Conclusion: There are unintended but potentially harmful consequences to cost-focused health policy interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenbaum S. Racial and ethnic disparities in healthcare: issues in the design, structure, and administration of federal healthcare financing programs supported through direct public funding. In: Smedley, Stith, Nelson, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press; 2003. 664–98

    Google Scholar 

  2. Rice T. The impact of cost containment efforts on racial and ethnic disparities in healthcare: a conceptualization. In: Smedley, Stith, Nelson, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press; 2003. 699–721

    Google Scholar 

  3. Institute of Medicine. In: Smedley, BD, Stith, AY, Nelson, AR, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Washington, DC: The National Academies Press; 2003.

  4. Lillie-Blanton M, Hoffman C. The role of health insurance coverage in reducing racial/ethnic disparities in health care. Health Affairs 2005; 24: 398–408

    Article  PubMed  Google Scholar 

  5. Seay M, Varma P. Pharmaceuticals: pharmaceutical cost controls — 2005. End of year issue brief. Issue Brief Health Policy Track Serv 2005; 1–20.

    Google Scholar 

  6. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in medicaid. Health Affairs 2004; 23: 135–46

    Article  PubMed  Google Scholar 

  7. Murawski MM, Abdelgawad T. Exploration of the impact of preferred drug lists on hospital and physician visits and the costs to medicaid. Am J Manag Care 2005; 11 (Special Issue): S35–42

    Google Scholar 

  8. Texas Health and Human Services Commission. Preferred drug list annual report. 2005. Available from: http://www.hhsc.state.tx.us/hcf/vdp/reports/010105_PDLAR.pdf. [Accessed 2006 Aug 1].

  9. Department of Medical Assistance Services. Virginia’s preferred drug list: program implementation outcomes and recipient health effects. 2005. Available from: http://www.dmas.virginia.gov/downloads/studies_reports/2005-RD214.pdf. [Accessed 2006 Aug 1].

  10. Alabama Medicaid Agency. Preferred drug and prior authorization program, criteria and instructions booklet. 2006. Available from: http://www.hidmedicaid.com/Forms/Criteria_Instruction_Booklet_10-2-06.pdf. [Accessed 2006 Aug 1].

  11. US Census Bureau. 1999 US postal service zip codes. Available from: http://www.census.gov/geo/www/tiger/zip1999.zip. [Accessed 2006 Feb 1].

  12. US Census Bureau. Annual estimates of the population for counties: April 1 2000 to July 1 2005. Available from: http://www.census.gov/popest/counties/CO-EST2005-01.html. [Accessed 2006 Feb 1].

  13. US Census Bureau. Census 2000 summary file 3 (sf 3). Available from: http://factfinder.census.gov/servlet/DatasetMainPageServlet?_ds_name=DEC_2000_SF3_U&_program=DEC&_lang=en. [Accessed 2006 Feb 1].

  14. Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Quart J Econ 2004; 119: 249–75

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pfizer Inc., 235 East 42nd Street, New York, New York, 10017, USA

    Tamer Abdelgawad & Lisa Egbuonu-Davis

  2. Spelman College, Atlanta, Georgia, USA

    Lisa Egbuonu-Davis

Authors
  1. Tamer Abdelgawad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa Egbuonu-Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tamer Abdelgawad.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abdelgawad, T., Egbuonu-Davis, L. Preferred Drug Lists and Medicaid Prescriptions. PharmacoEconomics 24 (Suppl 3), 55–63 (2006). https://doi.org/10.2165/00019053-200624003-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200624003-00005

Keywords

Search

Navigation